RespireRx Pharmaceuticals Inc (RSPI):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:RespireRx Pharmaceuticals Inc (RSPI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10064
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
RespireRx Pharmaceuticals Inc (RespireRx), formerly Cortex Pharmaceuticals, Inc., focuses on the discovery, development and commercialization of innovative products for the treatment of various respiratory disorders. It has two drug platforms, each with a clinical stage compound directed at breathing disorders. The company’s respiratory disease product pipeline includes compounds in various development stages for the treatment of obstructive sleep apnea (OSA), chronic and post-surgical central sleep apnea (CSA), opioid induced respiratory depression, spinal cord injury, and induced respiratory depression. Its lead product, Dronabinol, an oral capsule drug product completed Phase II trials for the treatment of OSA. RespireRx is headquartered in Glen Rock, New Jersey, the US.

RespireRx Pharmaceuticals Inc (RSPI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
RespireRx Pharma Raises Funds through in Venture Financing 11
RespireRx Pharma Raises USD0.1 Million in Financing 12
Partnerships 13
RespireRx Pharma Enters into Agreement Noramco 13
RespireRx Pharma Enters into Research Agreement with National Institute of Drug Abuse 14
Licensing Agreements 15
Cortex Pharma Enters into Licensing Agreement with University of Illinois 15
Samyang Optics Enters into Licensing Agreement with Cortex Pharma 17
Equity Offering 18
Cortex Pharma Raises USD0.7 Million in First Tranche of Private Placement of Units 18
Acquisition 19
Cortex Pharma Acquires Pier Pharma, Sleep Apnea Drug Development Company 19
RespireRx Pharmaceuticals Inc – Key Competitors 20
RespireRx Pharmaceuticals Inc – Key Employees 21
RespireRx Pharmaceuticals Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Aug 25, 2017: RespireRx Pharmaceuticals Files June 30, 2017 Quarterly Report on Form 10-Q And Provides Update 23
Product News 25
12/06/2017: Synthetic Cannabis-like Drug Reduces Sleep Apnea 25
Jul 25, 2018: RespireRx Pharmaceuticals Announces Publication of Ampakine Data 27
01/06/2017: RespireRx Pharmaceuticals to Present Data on CX-717 at 9th Annual Biotech Showcase 2017 28
Clinical Trials 29
Jan 08, 2018: RespireRx Pharma to Present on Dronabinol at 10th Annual Biotech Showcase 2018 29
Jan 08, 2018: RespireRx Pharmaceuticals to on CX-1739 Present at 10th Annual Biotech Showcase 2018 30
Dec 18, 2017: RespireRx Pharmaceuticals Publishes Compelling Scientific Evidence Demonstrating the Neurobiological Safety of Ampakine CX717 and Justifying Continued Clinical Development 31
Nov 30, 2017: RespireRx Pharmaceuticals Announces Publication of Phase 2B PACE Study: Once per Night Treatment with Dronabinol Provides Statistically Significant Improvement in Clinical Measures of Obstructive Sleep Apnea 32
Sep 08, 2017: RespireRx Pharmaceuticals to Present Update on Phase IIB Trial of CX1739 at 2017 Rodman & Renshaw Conference 34
Sep 08, 2017: RespireRx’s CEO to Present Clinical Trial plans for Dronabinol at 2017 Rodman & Renshaw Conference 35
Jun 14, 2017: RespireRx Pharmaceuticals to Present at the 2017 Marcum MicroCap Conference 36
Jun 06, 2017: RespireRx Pharmaceuticals Announces Participation SLEEP 2017 in Boston, MA 37
Feb 10, 2017: RespireRx Pharmaceuticals to Present Data on CX-1739 at BIO CEO & Investor Conference 2017 38
Feb 10, 2017: RespireRx Pharmaceuticals to Present Data on dronabinol at BIO CEO & Investor Conference 2017 39
Jan 06, 2017: RespireRx Pharmaceuticals to Present Data on CX1739 at 9th Annual Biotech Showcase 2017 40
Jan 06, 2017: RespireRx Pharmaceuticals to Present Data on Dronabinol at 9th Annual Biotech Showcase 2017 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
RespireRx Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
RespireRx Pharma Raises Funds through in Venture Financing 11
RespireRx Pharma Raises USD0.1 Million in Financing 12
RespireRx Pharma Enters into Agreement Noramco 13
RespireRx Pharma Enters into Research Agreement with National Institute of Drug Abuse 14
Cortex Pharma Enters into Licensing Agreement with University of Illinois 15
Samyang Optics Enters into Licensing Agreement with Cortex Pharma 17
Cortex Pharma Raises USD0.7 Million in First Tranche of Private Placement of Units 18
Cortex Pharma Acquires Pier Pharma, Sleep Apnea Drug Development Company 19
RespireRx Pharmaceuticals Inc, Key Competitors 20
RespireRx Pharmaceuticals Inc, Key Employees 21
RespireRx Pharmaceuticals Inc, Subsidiaries 22

List of Figures
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
RespireRx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[RespireRx Pharmaceuticals Inc (RSPI):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Martinrea International Inc:企業の戦略・SWOT・財務情報
    Martinrea International Inc - Strategy, SWOT and Corporate Finance Report Summary Martinrea International Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • SPAGO Nanomedical AB-医療機器分野:企業M&A・提携分析
    Summary Spago Nanomedical AB (SPAGO Nanomedical), formerly SPAGO Imaging AB is a drug company that develops proprietary magnetic resonance imaging contrast agent, and the novel therapeutic project tumorad for cancer selective radionuclide treatment. The company concentrates on research and developme …
  • Mesoblast Ltd (MSB):企業の財務・戦略的SWOT分析
    Mesoblast Ltd (MSB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Kimball Electronics, Inc. (KE):企業の財務・戦略的SWOT分析
    Kimball Electronics, Inc. (KE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Hokuriku Electric Power Co (9505):企業の財務・戦略的SWOT分析
    Hokuriku Electric Power Co (9505) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Outlook Therapeutics Inc (ONSIU):企業の財務・戦略的SWOT分析
    Summary Outlook Therapeutics Inc (Outlook Therapeutics), formerly Oncobiologics Inc, is a biopharmaceutical company that develops, manufactures and commercializes biosimilar products in the areas of ophthalmology. The company is investigating its lead product candidate, ONS-5010 an ophthalmic formul …
  • Opiant Pharmaceuticals Inc (OPNT):製薬・医療:M&Aディール及び事業提携情報
    Summary Opiant Pharmaceuticals Inc (Opiant), formerly, Lightlake Therapeutics Inc is a specialty pharmaceutical company that develops pharmacological treatments for substance use, addiction and eating disorders. It focuses on developing treatments to reverse opioid overdoses, for overweight and obes …
  • Intra Energy Corporation Ltd (IEC):電力:M&Aディール及び事業提携情報
    Summary Intra Energy Corporation Limited (IEC), formerly Atomic Resources Limited, is a mining and energy company that operates through subsidiaries, affiliates, and joint ventures. It explores and mines coal, mineral resources, ore reserves, and uranium through operating interests in various mines. …
  • Rubis SCA (RUI):企業の財務・戦略的SWOT分析
    Rubis SCA (RUI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Great Eastern Energy Corp Ltd (GEEC):企業の財務・戦略的SWOT分析
    Summary Great Eastern Energy Corp Ltd (GEECL), a subsidiary of YKM Holdings Pvt Ltd, is an oil and gas exploration and production company. The company carries out extraction and sale of coal bed methane coalbed methane gas. It operates upstream, midstream and downstream projects in Raniganj south bl …
  • Euro India Fresh Foods Ltd (EIFFL):企業の財務・戦略的SWOT分析
    Euro India Fresh Foods Ltd (EIFFL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Evertec Inc (EVTC):企業の財務・戦略的SWOT分析
    Summary Evertec Inc (Evertec) is a technology and communication company that offers transaction processing services. The company’s services include payment processing, merchant acquiring and business process management. Its payment processing services comprise card issuing and acquiring processing; …
  • BNK Petroleum Inc (BKX):石油・ガス:M&Aディール及び事業提携情報
    Summary BNK Petroleum Inc (BNK Petroleum) is an oil and gas company. The company explores, produces and acquires large hydrocarbon reserves. The company’s project includes Tishomingo Field, Gapowo B-1 well and other operations in Spain. Its Tishomingo Field is located in Ardmore Basin in Oklahoma, t …
  • F. Hoffmann-La Roche Ltd (ROG):企業の財務・戦略的SWOT分析
    F. Hoffmann-La Roche Ltd (ROG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Athenex Inc (ATNX):製薬・医療:M&Aディール及び事業提携情報
    Summary Athenex Inc (Athenex), formerly Kinex Pharmaceuticals LLC, is a biopharmaceutical company focused on the discovery, development and commercialization novel medicines and cell therapies for the treatment of cancers. The company’s orascovery products candidates include oral formulations of pac …
  • Regis Healthcare Ltd:企業の戦略・SWOT・財務情報
    Regis Healthcare Ltd - Strategy, SWOT and Corporate Finance Report Summary Regis Healthcare Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Korea Petrochemical Ind. Co Ltd (006650):企業の財務・戦略的SWOT分析
    Summary Korea Petrochemical Ind. Co Ltd (KPICL) is a chemical company that manufactures and markets petrochemical products. The company provides products such as olefins, aromatics, polypropylene, EO and EG, PP and HDPE. It provides olefins products such as ethylene, propylene, butene, butane, isobu …
  • Sequana SA (SEQ):企業の財務・戦略的SWOT分析
    Sequana SA (SEQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Dai Nippon Printing Co Ltd (7912):企業の財務・戦略的SWOT分析
    Dai Nippon Printing Co Ltd (7912) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • KSK Energy Ventures Ltd:発電所・企業SWOT分析
    KSK Energy Ventures Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emplo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆